BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 6, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 20, 2002
View Archived Issues
Improved pharmacokinetic profile reported for new nasal nicotine formulation
Read More
Improvement of natural learning impairment after administration of H3 receptor antagonists in rats
Read More
Daily Z-335 is safe and effectively blocks thromboxane A2 receptors
Read More
DAC:Opioid returns mixed results
Read More
Crucell licenses PER.C6 cell line for use in GenVec's BioBypass
Read More
Adolor enters opioid antagonist license agreement with Lilly
Read More
ARC enters research agreement with McGill University for antisense oligonucleotide therapeutics
Read More
ProdiGene and NIAID to begin phase I trial of oral traveler's diarrhea vaccine
Read More
Phase I solid tumor trial initiated for KSP inhibitor
Read More
Salicylate protects against the ototoxic and nephrotoxic side effects of cisplatin in rats
Read More
Iressa NSCLC trial results show no improvement in combined treatment with standard chemotherapy
Read More
Potent, selective and orally bioavailable FTase inhibitor presented by Abbott
Read More
Ras-MAPK signaling cascade inhibitors prepared and tested at Wyeth
Read More
Abbott reports novel HDAC inhibitors at the ACS meeting
Read More
Merck & Co. discloses novel HIV protease inhibitors
Read More
Nocathiacin I derivatives with in vivo antibacterial activity presented at ACS
Read More
New PPARalpha/delta receptor agonists covered by GSK patent
Read More
Merck claims alphavbeta3 and/or alphavbeta6 antagonists for cardiovascular and other disorders
Read More
Novel prostaglandin EP4 antagonists and their use in neuropathic pain
Read More